Glaucoma
Conditions
Brief summary
Images captured on the P200TE device on glaucoma patients
Interventions
DEVICEP200TE
SLO and OCT imaging
Sponsors
Optos, PLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects were 22 years of age or older on the date of informed consent; * Subjects were able to understand the written informed consent and willing to participate as evidenced by signing the informed consent; * BCVA 20/40 or better in the study eye; * History of visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings: On pattern deviation (PD), there existed a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; or Glaucoma hemi-field test "outside normal limits;" -Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities: Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage; and Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.
Exclusion criteria
* Subjects unable to tolerate ophthalmic imaging; * Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in the study eye; * Subject has a condition or is in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study; * No reliable visual field test result within the past year of the study visit, defined as fixation losses \> 33% or false positives \>33%, or false negatives \>33% in the study eye; * Presence of any ocular pathology except glaucoma in the study eye.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of images collected | 1 year |
Countries
United States
Outcome results
None listed